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detected in four patients (8.3 %). None of those events was 
associated with clinical deterioration. MCA curvature sig-
nificantly influenced recanalization success (P < 0.005).
Successful recanalization correlated significantly with lo-
wer NIHSS scores and favorable clinical outcome (mRS sco-
re 0–2) at discharge (P < 0.05). Mortality within 90 days was 
significantly lower in patients with TICI 2b/3 (P < 0.005).
Conclusions High recanalization rates, low complication 
rates, and a significantly improved outcome after success-
ful recanalization strongly suggest that MT with pREset is 
an adequate therapy for AIS after MCA occlusion. Vessel 
curvature is a significant determining factor for recanaliza-
tion success.
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Abstract
Purpose The purpose of this study was to analyze the safety 
and efficacy of the pREset device, a stent retriever system, 
for endovascular mechanical thrombectomy (MT) in acute 
ischemic stroke (AIS) after middle cerebral artery (MCA) 
occlusion.
Methods Retrospectively, 48 consecutive patients (mean 
age ± standard deviation, 71.0 ± 11.9 years; 24 women) 
treated for acute MCA occlusion using pREset solely or in 
combination with other MT devices were identified. Recan-
alization success was evaluated using the modified throm-
bolysis in cerebral infarction score (TICI), and complica-
tions were detected by 24-h follow-up computed tomogra-
phy or magnetic resonance imaging. MCA anatomy was as-
sessed in angiograms. Clinical outcome was evaluated with 
National Institutes of Health Stroke Scale (NIHSS) score at 
admission and discharge, and modified Rankin scale (mRS) 
score at discharge and follow-up.
Results Successful recanalization (TICI 2b/3) was achieved 
in 39 patients (81.3 %). Rate of procedure-related compli-
cations was 8.3 %. In four patients, a subarachnoid hemor-
rhage occurred (8.3 %), and parenchymal hematoma was 
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Introduction
Acute ischemic stroke (AIS) is one of the leading causes 
of morbidity and mortality in industrialized countries, with 
increasing importance due to the aging population [1]. While 
data suggest that intravenous thrombolysis using recombi-
nant tissue plasminogen activator (IV rtPA) is barely effec-
tive in large-vessel occlusion [2–4], devices and techniques 
for endovascular mechanical thrombectomy (MT) improved 
rapidly in the past years.
Initially, previous randomized controlled trials (RCT), 
which analyzed clinical outcome after the treatment of AIS, 
after using first-generation devices such as the Penumbra 
aspiration system (Penumbra, Alameda, CA, USA) or Merci 
Retriever (Concentric Medical, Mountain View, CA, USA), 
showed no significant superiority of MT over IV rtPA [5–7].
Simultaneously, second-generation self-expanding, 
removable, stent-like thrombectomy devices—named 
stent retrievers—were developed. They are designed to be 
deployed within the thrombus, where the stent mesh par-
tially penetrates the thrombotic material while expanding. 
This leads to adhesion of the clot to the stent retriever wall. 
Both the device and the thrombus are then retrieved into an 
aspiration or guiding catheter.
More recent studies compared these modern devices 
with the first-generation devices, which were predominantly 
used in the initial trials, and reported an explicit superiority 
of stent retrievers, particularly regarding highly increased 
recanalization rates and significantly improved clinical out-
come [8–17].
Due to these recent findings, the value and validity of the 
conclusions of the initial RCTs were debated, and concur-
rently, further advanced MT devices were developed.
In this study, we report our first clinical experiences with 
the pREset thrombectomy retriever (phenox, Bochum, Ger-
many). Mordasini et al. [18] recently described experimental 
results of this device in a swine model. Recanalization rates 
have been reported to be 93.8 % for complete recanalization 
(modified thrombolysis in cerebral infarction score (TICI) 
3) and 6.2 % for partial recanalization (TICI 2b), which are 
comparable to results of previous animal models, evaluat-
ing the Solitaire FR Revascularization Device (Covidien, 
Dublin, Ireland) and Trevo Retriever (Concentric Medical, 
Mountain View, CA, USA) devices [19–21]. Kurre et al. 
[22] recently described the first clinical experience using the 
pREset for the treatment of AIS. An overall rate of success-
ful recanalization (TICI 2b/3) of 94.8 % was reported, while 
including patients with occlusion of the carotid-T, M1, and 
M2 segments as well as vessels of the posterior circulation 
(i.e., V4 segment, basilar artery, and P1 segment).
In this study, we focused on a homogenous population 
of patients with one-sided occlusion of the first middle 
cerebral artery (MCA) segment (M1 segment) only. We 
analyzed recanalization efficacy, complication rates, MCA 
anatomy, and clinical and functional outcome and distin-
guished patient groups according to technical success of 
recanalization.
Materials and Methods
Patients, Therapy Strategy, and Clinical Data
Between October 2011 and November 2012, 48 patients 
(mean age ± standard deviation (SD), 71.0 ± 11.9 years; 24 
women) with symptomatic AIS induced by occlusion of 
either the left or the right M1 segment of the MCA were 
treated with MT using the pREset device either solely or in 
combination with several different devices. These patients 
were identified retrospectively searching our institution’s 
database, while complete imaging data, clinical reports, and 
procedure details were mandatory inclusion criteria.
Following our institution’s standard operating proce-
dures (SOPs), a relevant neurological deficit of at least four 
points according to the National Institutes of Health Stroke 
Scale (NIHSS) was required for therapy.
Preinterventionally, IV rtPA was applied within a time 
frame of 4.5 h after observed symptom onset if there were 
no contraindications, following the guidelines by the Ger-
man Society of Neurology [23]. Patients received a dose of 
0.9 mg rtPA per kilogram of their body weight, whereupon 
10 % of the total dose was applied as immediate loading dose 
and the remaining 90 % during the following hour. IV rtPA 
was continued until the full dose was administered, regard-
less of whether angiography and MT were commenced in 
the meantime.
MT was performed in patients with an MCA occlusion 
in the M1-segment that presented within a time frame of 
6 h after symptom onset or 3 h after discovery in wake-up 
stroke patients. Contraindications for MT were intracranial 
hemorrhage and distinct infarct demarcation of more than 
one-third of the MCA territory in initial cranial computed 
tomography (cCT).
NIHSS score was assessed at admission by an experi-
enced stroke neurologist for baseline evaluation of the 
patient’s clinical status [24, 25]. NIHSS score was re-
assessed at discharge in 47 patients (97.9 %). NIHSS score 
differences were calculated between the scores at admission 
and discharge, while an improvement of at least four points 
was considered significant. The degree of dependence was 
assessed using the modified Rankin Scale (mRS) at dis-
charge in 46 patients (95.8 %) and after a mean follow-
up time of 205 days (SD, ± 135.6) in 43 patients (89.6 %) 
through either a standardized telephone or personal inter-
view by trained physicians or evaluated medical reports 
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pusher wire. This configuration intends to stabilize the 
proximal opening of the device, to provide a constant radial 
force, and therefore especially avoids tapering in curved 
vessels. There is one radiopaque marker at the connection 
point between the proximal ring and the pusher wire, and 
there are two additional markers at the most distal ends of 
the cell structure. The pREset is available in two different 
sizes, 4/20 and 6/30, where the first number represents the 
maximal diameter in millimeters and the latter the usable 
length. As usable length, the manufacturer determines the 
distance between the distal markers and the closed ring at 
the proximal end of the device. The device was CE marked 
in Europe in August 2011. For this retrospective analysis, 
the pREset 4/20 was used solely.
Endovascular Treatment and Evaluation
Depending on patients’ compliance, endovascular pro-
cedures were performed under general anesthesia in 41 
patients (85.4 %), while the remaining patients were treated 
under conscious sedation and analgesia. An 8F guid-
ing catheter (Vista Brite Tip, Cordis) for cervical access 
was placed through a short 8F sheath after puncture of 
the femoral artery. By a three-axial approach, a 0.054-
inch intermediate catheter (5MAX, Penumbra) containing 
a 0.021-inch microcatheter (Trevo Pro 18, Stryker) and a 
0.014-inch microwire (Traxcess 14, Terumo) was advanced 
intracranially. The occluded M1 segment was passed with 
the microwire and the microcatheter. In this position, the 
pREset was deployed, covering the proximal and the distal 
thrombus borders. After a delay of 5 min, the intermediate 
catheter was advanced to the proximal thrombus site using 
the deployed stent retriever as an anchor. Subsequently, 
the device was retrieved under constant manual aspiration 
into the intermediate catheter. In two patients, a balloon-
equipped guiding catheter (Merci Balloon Guided Catheter, 
Stryker) without an intermediate catheter was used instead 
of the guiding catheter mentioned, following the individual 
decision of the interventionalist.
This procedure was repeated until successful recanaliza-
tion was achieved, or it was aborted in case of excessive 
procedural time and negligible chances for success. In this 
analysis, the pREset device was used as first-line device and 
in combination with other devices in 15 patients (31 %), 
according to the performing interventionalist’s individual 
decision.
Recanalization results were graded in the final angiogram 
using the modified thrombolysis in cerebral infarction score 
(TICI). TICI of 2b and 3 were considered as successful 
recanalization [27].
Additionally, anterior-posterior (AP)  projections of the 
final angiograms were assessed for MCA anatomy evalu-
ation (Fig. 2). Similar to the technique described by Zhu 
compiled by the respective rehabilitation clinic [26]. An 
mRS score of 0–2 was defined as favorable outcome.
Time durations were measured: from symptom onset to 
groin puncture, from symptom onset to reperfusion or end of 
procedure in case of unsuccessful recanalization, and from 
groin puncture to reperfusion or end of procedure. In five 
cases, time from symptom onset to femoral artery puncture 
was imprecise, but definitely ranged within the time win-
dow of 6 h, and no infarct demarcation was shown on the 
native cCT scan immediately before intervention.
Imaging Data
All patients underwent a cCT scan either on a 64-row or a 
256-row CT scanner (Philips Brilliance 64/Brilliance iCT; 
both Philips Medical Systems B.V., Best, the Netherlands) 
immediately at admission, to rule out hemorrhage or infarct 
demarcation. In addition, a CT angiography was performed 
to verify the occlusion type and to analyze vessel pattern. 
Within 24 h after endovascular treatment and in case of 
clinical deterioration, a further cCT or magnetic resonance 
imaging (MRI) scan was performed to assess postproce-
dural complications. The complete imaging data including 
angiograms were re-evaluated for this study by two neuro-
radiologists in consensus reading (S. Prothmann and B.J. 
Schwaiger).
The pREset Device
The pREset device is a laser-cut nitinol stent, inseparably 
attached to a 180-cm pusher wire (Fig. 1). The stent wall 
design features a closed-cell pattern, while a slit is left out 
that spirals the wall in a helical pattern. This allows the 
device to expand and contract depending on the vessel 
diameter, while sustaining the cell configuration, according 
to manufacturer’s information. The proximal cells merge 
into a closed ring, which is eccentrically connected to the 
Fig. 1 The pREset 4/20 in clinical use. The image shows the fully 
expanded device with its closed-cell structure connected to a proximal 
closed ring (asterisk), which eccentrically merges into the pusher wire 
(right arrow). At this connection point, there is one radiopaque marker, 
while there are two more at the distal end of the working length (left 
arrow). Note the thrombotic material retrieved out of the M1 segment 
of a 56-year-old female patient, whose final angiogram was graded 
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Three patients were admitted after wake-up stroke with 
unknown time from symptom onset to reperfusion, while in 
the remaining patients, mean time between observed symp-
tom onset and groin puncture was 246 min (SD, ± 88.0 min). 
The average procedure time was 54 min (SD, ± 35.6 min). 
Between subgroups of patients with versus without success-
ful recanalization, there were no significant differences in 
demographic parameters, NIHSS score at admission, and 
reported time windows.
A successful recanalization (TICI 2b/3) was achieved in 
39 patients (81.3 %). Concerning the analysis of vessel con-
figuration, patients with a curved MCA were significantly 
more often recanalized unsuccessfully than those with a less 
angulated MCA (2.6 versus 44.4 %; P < 0.005).
Focal SAH was found in five patients (10.4 %) on the 
24-h follow-up images, while none of these patients pre-
sented clinical worsening. Diffuse SAH was not found in 
any patient. In one patient (2.1 %), SAH was observed dur-
ing the procedure, while a definite vessel perforation was 
not detected. To achieve hemostasis in one case of a docu-
mented microwire perforation, one frontal MCA branch 
was occluded using a single fiber coil, and the final angio-
gram was graded TICI 2b at the end of the procedure. In 
this patient, there was no SAH-related clinical worsening as 
well and he was discharged, showing an NIHSS score of 7. 
At follow-up, he presented with an mRS score of 2. In one 
patient (2.1 %), a dissection of the cervical segment of the 
internal carotid artery was induced by inflation of a catheter-
mounted balloon. As no hemodynamic effect was recorded 
in the final angiogram as well as sonographically immedi-
ately after the procedure, no further therapy was performed. 
In one patient (2.1 %), the thrombus was dislocated from the 
et al. [28], and to the experience of our interventionalists, 
the curvature angle between the most proximal part imme-
diately emerging out of the carotid-T and the most distally 
contrasted part of the M1 segment was measured. A curva-
ture angle exceeding 80° was defined as curved MCA.
Perforation, dissection, thrombus dispersion, and focal or 
diffuse subarachnoid hemorrhage (SAH) were determined 
as procedure-related complications. Separately, stroke-
related hemorrhagic events (hemorrhagic infarction and 
parenchymal hematoma) were characterized according to 
the methods used in the ECASS trials [29]. Complications 
and hemorrhage were defined as clinically relevant if they 
were associated with an NIHSS score increase of four points 
or more.
Statistical Analysis
In addition to descriptive statistics, Fisher’s exact test was 
used for categorical data, the exact Mann–Whitney U test 
for nonparametric testing, and Student’s or Welch’s t-test 
for continuous data, depending on equality of variances. All 
tests were performed using a two-sided 0.05 level of signifi-
cance. Statistical analyses were performed using IBM SPSS 
Statistics, release 21 (IBM, Armonk, NY, USA) and super-
vised by a statistician.
Results
A total of 48 consecutive patients (mean age ± SD, 71.0 ± 11.9 
years, 24 female) were included in the study (Table 1). 
Median NIHSS score at admission was 15 (range, 2–27). 
Fig. 2 Baseline (a) and final (b) 
angiograms of the right internal 
carotid artery and the right MCA 
of a 73-year-old male patient. 
The angle between the proximal, 
nearly horizontal part and the 
more distal part of the M1 seg-
ment after the curvature measures 
104.6°. After four futile passages 
with pREset and Solitaire stent 
retrievers, the procedure was dis-
continued and the final angiogram 
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hemorrhagic infarction (HI1) and eight patients (16.7 %) 
with more confluent petechial hemorrhagic infarction (HI2), 
while three patients (6.3 %) showed parenchymal hematoma 
with mild space-occupying effect (PH1) and one patient 
(2.1 %) showed significant space-occupying effect (PH2). 
In none of these cases, hemorrhage was considered as clini-
cally relevant. Regarding hemorrhage rates, there were no 
significant differences between the TICI 0–2a and TICI 2b/3 
subgroups.
Patients in the TICI 2b/3 subgroup had significantly 
lower absolute NIHSS values at discharge compared with 
patients in the TICI 0–2a subgroup (median, 5 versus 11; 
P < 0.05), while no significant differences between the 
subgroups were found in NIHSS improvement, which is 
defined as the difference between NIHSS score at admis-
proximal section to the distal section of the M1 segment, 
while a small thrombus fragment was scattered and embo-
lized into a small frontal MCA branch. After a further suc-
cessful passage, the final angiogram was graded TICI 2b, 
and the patient was discharged, presenting an NIHSS score 
of 0. A hemodynamically relevant vasospasm of the M1 seg-
ment was observed in one patient (2.6 %), after three pas-
sages with two different devices (pREset and Trevo 4/20). 
With a delay of 5 min, the vasospasm remitted spontane-
ously, and consequently no further therapy was performed. 
However, only partial recanalization was achieved in this 
patient (TICI 2a), and at discharge, the patient presented an 
NIHSS score of 10.
According to the ECASS classification for hemorrhagic 
events, there were four patients (8.3 %) with small petechial 
Table 1 Epidemiological, clinical, and technical parameters as well as outcome of all patients and comparison between subgroups depending on 
recanalization success
Parameter All patients TICI 0–2a TICI 2b/3 P-value
Group/subgroup size 48 9 (18.7 %) 39 (81.3 %)
Female sex (n; % of 
subgroup)
24 (50 %) 3 (33.3 %) 21 (53.8 %) 0.461
Age (years; mean ± SD) 71.0 ± 11.9 66.4 ± 10.4 72.1 ± 12.1 0.203
Wake-up (n; % of 
subgroup)
3 (6.3 %) 0 (0.0 %) 3 (7.7 %) 1,000
Time from symptom onset 
to puncture (min; mean 
± SD)a
246 ± 88.0 229 ± 124.1 249 ± 81.1 0.573
Procedure time (min; mean 
± SD)b
54 ± 35.6 67 ± 42.2 51 ± 34.3 0.276
Time from onset to recana-
lization (min; mean ± SD)a
299 ± 94.9 296 ± 139.3 300 ± 86.5 0.920
IV rTPA administered (n; 
% of subgroup)
34 (65.4 %) 4 (44.4 %) 30 (76.9 %) 0.099
Passages of device (n; 
median, range)
2 (1 to 8) 4 (1 to 8) 2 (1 to 6) 0.023*
More than one device used 
(n; % of subgroup)
16 (33.3 %) 6 (66.7 %) 10 (25.6 %) 0.044*
Curved MCA (n; % of 
subgroup)
5 (10.4 %) 4 (44.4 %) 1 (2.6 %) 0.003*
NIHSS score at admission 
(median, range)
15 (2 to 27) 15 (9 to 24) 15 (2 to 27) 0.912
NIHSS score at discharge 
(median, range)c
7 (0 to 43) 11 (3 to 43) 5 (0 to 43) 0.018*
NIHSS improvement 
(median, range)c
− 7 (− 20 to 34) 0 (− 8 to 34) − 7 (− 20 to 30) 0.094
NIHSS improvement more 
than four points (n; % of 
subgroup)c
34 (72.3 %) 4 (44.4 %) 30 (76.9 %) 0.191
mRS score 0–2 at 
dischargeb
17 (37.0 %) 0 (0 %) 17 (45.9 %) 0.017*
mRS score 0–2 at 
follow-upa
18 (41.9 %) 1 (12.5 %) 17 (48.6 %) 0.111
Death within 90 days (n; 
% of subgroup)a
8 (18.6 %) 5 (62.5 %) 3 (8.6 %) 0.003*
Data missing for n patients (an = 5; bn = 2; cn = 1)
*Significant on the level P < 0.05
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Discussion
In this study, we have shown that treatment of AIS caused by 
MCA occlusion using the pREset stent retriever is associated 
with high recanalization rates and a low risk of procedure-
related complications such as vessel perforation, dissection, 
or thrombus dispersion. These findings are congruent with 
the results of the experimental in vivo model, as reported 
by Mordasini et al. [18], as well as with the first clinical 
experience with the same device, as reported by Kurre et 
al. [22]. In contrast to the latter, in which patients with dif-
ferent occlusion patterns of the anterior and posterior cir-
culation were included, we focused on patients with MCA 
M1 segment occlusion only. Kurre et al. reported recanali-
zation rates of 76.4 % within three passages with the pREset 
device solely and 94.8 % overall (if the number of passages 
or number of different devices used was not taken into con-
sideration). These results are comparable to the recanaliza-
tion rate of 81.3 %, which was achieved in this study.
Many recent studies show the superiority of stent retriev-
ers over first-generation devices regarding recanalization 
success [8–17]. Recanalization rates achieved in this study 
are comparable to rates reported by a multicenter evaluation 
of the Solitaire (79.2 %) and a combined analysis of Soli-
taire and Trevo (82 %) [12, 30]. Also, adverse event rates 
are comparable to those reported (7.4–10 %) [12, 17, 30].
Recanalization rates correlated significantly negatively 
with the number of passages necessary as well as with the 
number of different devices used. This is plausible, as, 
for example, in patients with complicated vessel geom-
etry or resistant thrombus composition, different technical 
approaches are attempted, often leading to poor final results, 
irrespective of the number of passages.
The potential to identify factors determining recanaliza-
tion success was limited in this retrospective study. However, 
we analyzed the anatomy of the M1 segment in correlation 
with recanalization results. To our knowledge, the influence 
of vessel anatomy, assessed in angiograms, on recanaliza-
tion results has not been investigated before. There is only 
one previous study based on pre-interventional MRI. Zhu et 
al. [28] analyzed clot shape and vessel curvature as shown 
by the susceptibility vessel sign in axial T2* gradient echo 
sequences, and its influence on recanalization results. The 
curved shape of the MCA significantly diminished chances 
for technical and clinical success of MT using the MERCI 
retriever, a first-generation thrombectomy device, which 
is obsolete in most cases by now. However, the effects of 
vessel curvature concerning the efficacy of second-gener-
ation devices such as Solitaire, Trevo, or pREset remained 
unclear so far. In this study population, we have found that 
in patients presenting an MCA curvature with more than 
80° measured in the AP-projection angiogram, a successful 
recanalization is significantly less likely. It has to be noted 
sion and discharge. Successful recanalization was signifi-
cantly associated with favorable mRS values at discharge 
(45.9 versus 0.0 %; P < 0.05; Fig. 3). At follow-up, patients 
of the TICI 2b/3 subgroup showed a good functional out-
come more often (mRS score ≤ 2) than those of the TICI 
0–2a subgroup; however, this difference was not significant 
(48.6 versus 12.5 %; P > 0.05). Mortality within 90 days was 
significantly lower in patients in the TICI 2b/3 subgroup 
(8.6 versus 62.5 %; P < 0.005; Fig. 3).
No significant influence of IV rtPA application on recana-
lization success or any of the analyzed clinical and func-
tional outcome parameters was found (P > 0.05).
Patients treated under general anesthesia had significantly 
higher NIHSS scores at admission than patients treated 
under conscious sedation and analgesia (P < 0.05), while the 
NIHSS score differences after MT treatment did not differ 
significantly between these patients (P > 0.05). Technical 
recanalization results and mRS scores at follow-up were not 
influenced significantly by the type of anesthesia (P > 0.05).
Fig. 3 Shift analyses showing mRS values at discharge and follow-
up of patients after successful (TICI 2b/3) versus unsuccessful (TICI 
0–2a) recanalization. After successful recanalization, significantly 
more patients presented a favorable outcome (mRS score 0–2) at dis-
charge (asterisk, P < 0.05). At follow-up, however, this distinct trend 
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85.4 % of the patients included in this study were treated 
under general anesthesia, which is comparable to the num-
bers reported by the ENDOSTROKE registry (93 %) [38]. 
However, due to the small sample size, we were not able 
to analyze the impact of anesthesia type on recanalization 
success.
This retrospective analysis focused primarily on the 
safety and technical efficacy of the pREset device. We also 
analyzed mid-term clinical outcome; however, a standard-
ized 3-month follow-up was not yet part of our institutional 
SOPs at the time the patients were treated. As a result, there 
was an increased variance in follow-up time, which dimin-
ished the value of clinical mid-term follow-up data. Another 
limitation of the study was the small size of the TICI 0–2a 
subgroup. Subsequently, logistic regression models or other 
statistical means suitable for larger analyses were consid-
ered as unstable, and more robust tests not correcting for 
age, recanalization times, or comorbidities, for example, 
had to be employed. That no significant differences between 
the subgroups were found regarding NIHSS improvement 
and mRS at follow-up may be caused by these limitations.
Conclusion
This clinical data presented showed high recanalization 
rates and low complication rates in patients treated with 
the pREset stent retriever. Patients showed a significant 
clinical outcome improvement after successful recanali-
zation. These findings suggest that MT with the pREset, 
representing second-generation thrombectomy devices, is 
an adequate therapy for AIS induced by MCA occlusion. 
The finding that recanalization success is significantly influ-
enced by MCA anatomy should further be investigated.
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